InvestorsHub Logo
Followers 24
Posts 10167
Boards Moderated 0
Alias Born 02/01/2013

Re: None

Saturday, 06/23/2018 7:58:40 AM

Saturday, June 23, 2018 7:58:40 AM

Post# of 403754
I will re-post what Leo said to me. I didn't respond to the poster's question yesterday because I am limited currently to one post/day.

Of course we are concerned about the stock price. As stated in our recent 10-Q, we are moving forward with partnering discussions. These things take time. In addition, we are expecting Prurisol data lock by our CRO; new batches of Brilacidin (Evonik); and communicating with FDA on OM. As soon as funds are available for Kevetrin we expect to complete the tox bridging study and get right back into the clinic.
Yesterday a report came out addressing the potential size of the OM market, Diamond Equity Research Initiates Coverage on Oragenics Inc. I encourage you to read it and see the potential need and size of the OM market.
https://globenewswire.com/news-release/2018/06/20/1527305/0/en/Diamond-Equity-Research-Initiates-Coverage-on-Oragenics-Inc-NYSE-OGEN-with-a-Valuation-of-3-50-Per-Share.html


The OM results we achieved are outstanding. The market size and yearly profits that are possible with an approved OM drug are multiples of our market cap. We are trying as hard as we can and as fast as we can, to get there.

Regarding the raise at 25 cents we needed and used the funds to pay the CRO's and start the process for the manufacture of Brilacidin for the next clinical trials.